跳转至内容
Merck
  • Strength and function response to clinical interventions of older women categorized by weakness and low lean mass using classifications from the Foundation for the National Institute of Health sarcopenia project.

Strength and function response to clinical interventions of older women categorized by weakness and low lean mass using classifications from the Foundation for the National Institute of Health sarcopenia project.

The journals of gerontology. Series A, Biological sciences and medical sciences (2014-08-20)
Maren S Fragala, Thuy-Tien L Dam, Vanessa Barber, James O Judge, Stephanie A Studenski, Peggy M Cawthon, Robert R McLean, Tamara B Harris, Luigi Ferrucci, Jack M Guralnik, Douglas P Kiel, Stephen B Kritchevsky, Michelle D Shardell, Maria T Vassileva, Anne M Kenny
摘要

The Foundation for the National Institutes of Health Sarcopenia Project developed data-driven cut-points for clinically meaningful weakness and low lean body mass. This analysis describes strength and function response to interventions based on these classifications. In data from four intervention studies, 378 postmenopausal women with baseline and 6-month data were evaluated for change in grip strength, appendicular lean mass corrected for body mass index, leg strength and power, and short physical performance battery (SPPB). Clinical interventions included hormones, exercise, and nutritional supplementation. Differences in outcomes were evaluated between (i) those with and without weakness and (ii) those with weakness and low lean mass or with one but not the other. We stratified analyses by slowness (walking speed ≤ 0.8 m/s) and by treatment assignment. The women (72±7 years; body mass index of 26±5kg/m(2)) were weak (33%), had low lean mass (14%), or both (6%). Those with weakness increased grip strength, lost less leg power, and gained SPPB score (p < .05) compared with nonweak participants. Stratified analyses were similar for grip strength and SPPB. With lean mass in the analysis, individuals with weakness had larger gains in grip strength and SPPB scores regardless of low lean mass (p < .01). Older women with clinically meaningful muscle weakness increased grip strength and SPPB, regardless of the presence of low lean mass following treatment with interventions for frailty. Thus, results suggest that muscle weakness, as defined by the Foundation for the National Institutes of Health Sarcopenia Project, appears to be a treatable symptom.

材料
货号
品牌
产品描述

Sigma-Aldrich
β-雌二醇, BioReagent, powder, suitable for cell culture
Sigma-Aldrich
β-雌二醇, ≥98%
Sigma-Aldrich
β-雌二醇, powder, γ-irradiated, suitable for cell culture
Sigma-Aldrich
雌二醇, meets USP testing specifications
Sigma-Aldrich
反式-脱氢雄甾酮, ≥99%
Sigma-Aldrich
柠檬酸钙四水合物, 99%
Supelco
17β-雌二醇 溶液, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
脱氢表雄酮(DHEA)标准液 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
USP
雌二醇, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
β-雌二醇, analytical standard
Supelco
雌二醇, Pharmaceutical Secondary Standard; Certified Reference Material
雌二醇 半水合物, European Pharmacopoeia (EP) Reference Standard